Inclusion Criteria:

- Subjects must be women with a histologically confirmed invasive adenocarcinoma of the
breast (stage I, II, or III) with no evidence of metastatic disease.

- Patients must be planning to receive neoadjuvant or adjuvant chemotherapy. Patients
may receive concurrent trastuzumab as indicated. If a patient has not yet undergone
final surgical resection, it must be highly likely (but is not required to be
definite) that the patient will be treated with adjuvant chemotherapy.

- Patients must have:

- Reached their 25th birthday and not yet reached their 51st birthday at the time
of study enrollment, AND

- Had menses within 3 months prior to starting chemotherapy

- Patients must not have received prior cytotoxic chemotherapy for any oncologic,
rheumatologic, or dermatologic condition.

- Patients must not have had prior bilateral oophorectomy or pelvic radiation, and must
not have had prior hysterectomy

- ECOG performance status 0 - 2

- Pregnant or nursing women may not participate. Women of reproductive potential must
agree to use an effective non-hormonal contraceptive method, such as condoms, tubal
ligation, non-hormonal intrauterine device, partner sterilization, and abstinence
during chemotherapy.

- All patients must be informed of the investigational nature of this study and given
written informed consent in accordance with institutional and federal guidelines.